The Government of Mexico will make an evaluation of the efficacy of the Moderna laboratory vaccine against Covid-19 used as a booster, but in the meantime it is already applying it to the country’s teachers.
The teachers were vaccinated in the middle of last year with the single-dose vaccine from the Chinese pharmaceutical company CanSino, which was bottled in Querétaro.
According to studies, the injection prevents 65.7% of symptomatic cases of Covid-19, 95.47% of severe cases and 100% of hospitalizations.
After Moderna announced the donation of 2.7 million doses of its vaccine to Mexico, the government decided that these would be used as reinforcement for teachers.
Read also: The booster vaccination campaign for teachers begins
This morning, at the presidential morning conference, Foreign Minister Marcelo Ebrard indicated that only a joint clinical trial with the United States will be carried out to review the effectiveness of Moderna’s vaccine as a booster.
The foregoing, in the context that the neighboring country has not authorized the CanSino vaccine, but Moderna’s.
“In terms of clinical trials, we are going to carry out a trial together with the United States to evaluate Moderna as a booster dose for any other type of complete vaccination schedule, which would facilitate the issue of travel to the United States and trade . We are already working on this one”, affirmed Ebrard.
Meanwhile, the Moderna company itself recommended that the Mexican government study the effectiveness of its vaccine as a booster in people who previously received the dose of CanSino.
“It is an interesting opportunity to obtain data from the Moderna vaccine on individuals who have been pre-inoculated with CanSino, we will not be able to do that in England or a European country or in the United States, but we depend on the capacity of the countries” César Sanz, medical vice president of Moderna, commented in an interview, according to the newspaper The financial.
The manager assured that they have a study from the Singapore Ministry of Health, which determined that Moderna’s vaccine as a reinforcement of Pfizer’s has an efficacy of 82% for symptomatic Covid-19 with the Delta variant, which is being replaced globally by the Ómicron variant.
Do you already have us on Facebook? Give us like and receive the best information
–
